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Abstract. Increased amyloid- (A) accumulation associated with abnormal autophagy-lysosomal activity and nutrient
kinase dysregulation are common features in Alzheimer’s disease (AD) brain. Recent studies have identified PRKAG2 and
TIPRL genes that control nutrient kinase regulated autophagy, and here we determined if their expression is altered in
postmortem AD brains. Gene and protein expression of TIPRL were unchanged. However, gene expression of PRKAG2 was
increased 3-fold and its protein levels positively correlated with A accumulation in the AD brain. In summary, our findings
suggest that increased PRKAG2 is an important contributing factor to A accumulation in the AD brain.
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INTRODUCTION
Autophagy is an important clearance pathway for
misfolded and aggregate proteins and its dysfunc-
tion has been implicated in the impaired clearance
of aggregate proteins in neurodegenerative diseases
including Alzheimer’s disease (AD), frontotemporal
dementia (FTD), and Lewy body dementia (LBD).
The autophagy pathway is impaired at different steps
in various types of dementias and mostly associ-
ated with increased autophagy initiation and reduced
∗Correspondence to: Prashant Bharadwaj, Centre of Excellence
in Alzheimer’s Disease Research and Care, School of Medical and
Health Sciences, Ralph and Patricia Sarich Neuroscience Research
Institute, Edith Cowan University, Nedlands, WA, Australia. Tel.:
+61433579575; E-mail: p.bharadwaj@ecu.edu.au.
autophagosome degradation [1]. AD brain shows a
marked upregulation of lysosomal activity, includ-
ing extensive involvement of autophagosomes and
acid hydrolases such as cathepsin D with amyloid-
 (A) protein deposits [1, 2]. Whereas, LBD is
characterized by a decrease in Atg7 expression
which is predicted to result in deficient initiation
of the autophagic process [3]. A high proportion of
FTD cases have a hereditary component and several
pathogenic gene mutations impact pathways asso-
ciated with later steps of autophagy including the
CHMP2B (charged multivesicular body protein 2B)
and VCP (valosin containing protein) genes, which
lead to impaired autophagosome maturation [4].
Autophagy is closely regulated by nutrient sig-
naling kinases [mammalian (or mechanistic) target
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of rapamycin complex 1] (mTORC1) and AMP-
activated kinase (AMPK). mTORC1 and AMPK act
as the main upstream sensors, while Unc-51 like
autophagy activating kinase 1 (ULK1) complex inte-
grates the upstream signals and transduces them to the
downstream autophagy pathway [5]. Signaling from
mTORC1 and AMPK pathways is essential for regu-
lating anabolic and catabolic pathways and growing
evidence suggests that these nutrient sensing kinases
are dysregulated in AD and other neurodegenera-
tive diseases [6]. Studies have identified regulatory
genes PRKAG2 (Protein Kinase AMP-Activated
Non-Catalytic Subunit Gamma 2) and TIPRL (TOR
Signaling Pathway Regulator) that modulate the abil-
ity of AMPK and mTORC1 to control autophagy
during stress. AMPK is a heterotrimeric protein com-
plex composed of 3 subunits including a non-catalytic
regulatory gamma subunit PRKAG2. AMPK is an
evolutionarily conserved master switch in the cel-
lular energy balance activated during metabolic
stress [7] [8]. PRKAG2 homolog, SNF4A is
required for regulation of developmental and stress-
induced autophagy in a drosophila model [9]. TIPRL
facilitates amino-acid regulated mTORC1 signaling
through its association with protein phosphatase 2A
(PP2Ac). TIPRL promotes H2AX (histone H2A vari-
ant) phosphorylation during DNA damage [10] and
also functions as a negative regulator of autophagy
[11]. The above studies show an important role for
PRKAG2 and TIPRL in regulating nutrient kinase
signaling and autophagy during stress. But whether
their expression levels are altered in the AD brain
and if they are associated with impaired autophagy
and accumulation of A is unknown.
The main aim of this study was to determine the
gene and protein expression levels of autophagosome
marker microtubule-associated protein 1A/1B-light
chain 3B (LC3), lysosomal hydrolase Cathpesin D,
autophagy regulators PRKAG2 and TIPRL in frontal
cortex and hippocampal regions of postmortem brain
tissues of patients with AD, FTD, LBD, and in healthy
controls. We also assessed whether A accumulation
correlated with autophagy related proteins LC3BI,
LC3BII, Cathepsin D, PRKAG2, and TIPRL. Our
findings show that gene expression of PRKAG2 was
increased 3-fold in AD-hippocampus and AD-frontal
cortex and its protein levels positively correlated with
A accumulation in the brain. Whereas, gene and
protein expression of TIPRL were unchanged. Our
findings suggest that increased PRKAG2 may be an




All experiments were conducted in frontal cor-
tex (F) and hippocampus (H) regions of postmortem
brain tissues of patients with AD (n = 15), FTD
(n = 5), LBD (n = 5), and healthy controls (n = 5)
obtained from the Sydney Brain Bank (SBB),
approved by Human Research Ethics Commit-
tee of Edith Cowan University (approval number
14820).
cDNA synthesis and gene expression analysis in
brain homogenates
Frozen brain tissues (100 mg) were suspended
in 300l Tris-buffered saline (TBS), pH 7.4 with
ceramic beads and homogenized at 4000 RPM
for 3 cycles of 45 s using a MoBio PowerlyzerTM
at 4◦C. The brain homogenates were aliquoted
into 100l lots and stored at –80◦C. RNA and
cDNA preparation were prepared from the brain
homogenates using RNeasy lipid tissue mini extrac-
tion kit and Qiagen reverse transcription kit. For the
quantification of the products (RNA and cDNA),
QubitTM dsDNA HS Assay kits (ThermoFisher) were
used. Gene expression of autophagosome marker
LC3B (Hs00797944 s1), lysosomal hydrolase
Cathepsin D (CTSD, Hs00157205 m1), PRKAG2
(Hs00211903 m1), TIPRL (Hs00295580 m1) and
endogenous control Glyceraldehyde 3-phosphate
dehydrogenase (GAPDH, Hs03929097 g1) was
conducted on cDNA synthesized from brain
homogenates using Taqman assays on the QuantStu-
dio 12K system. Fold change in gene transcripts was
measured using comparative Ct method using the
QuantStudio(TM) Real-Time PCR Systems software
platform, with GAPDH as endogenous control and
frontal cortex from healthy controls (Cont-F) as the
reference biological group.
Westerns quantification for brain homogenates
Brain homogenates in TBS were used for western
blotting analysis and protein quantification of A,
LC3B isoforms LC3BI and LC3BII, Cathepsin D,
PRKAG2, TIPRL and control GAPDH. All samples
were loaded in duplicate using 4–12% BisTris gels,
including a pooled brain homogenate sample as an
internal control in each gel. An average of all the inter-
nal controls (mean internal control) for each antibody
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and an internal control factor for each gel was calcu-
lated. Average of the duplicate of every sample was
calculated and normalized using the internal control
factor for the respective gel. A antibody WO2 (3.5
kDa) was a generous gift from Prof. Colin Masters,
Melbourne. Other antibodies including GAPDH (37
kDa), LC3B (14 and 16 kDa), mature Cathepsin D
(30 kDa), PRKAG2 (60 and 75 kDa isoforms), and
TIPRL (32 kDa) were purchased from Cell Signaling
or Abcam.
Statistical analysis
To determine statistical significance for compar-
isons of gene and protein markers measured in brain
tissue samples as Mean±Standard Deviation (SD), 1-
way ANOVA was used, while Pearson’s correlation
was used to assess correlation. Statistical significance
was considered post-Tukey correction. All the sta-
tistical analyses were conducted on Graphpad Prism
software.
RESULTS
Increased PRKAG2 gene expression in AD brain
Increased accumulation of A and elevated lysoso-
mal activity are pathological hallmarks of AD, so we
initially assessed expression levels of these markers
in frontal cortex (F) and hippocampal (H) regions of
postmortem brain tissues of patients with AD, FTD,
LBD, and in healthy controls. We first assessed A
and GAPDH levels in postmortem brain tissues by
western immunoblotting (Fig. 2, Supplementary Fig-
ures 1 and 2). A was mostly detected as a monomer
at 4 kDa; however, its length was not known. A lev-
els were significantly higher in AD-F as compared
to Cont-F. A levels was also high in AD-H as com-
pared to Cont-H, but was not significant. LBD-F also
showed increased A levels, as compared to Cont-F
indicative of the AD like neuropathology routinely
observed in LBD brains [12]. Although our findings
show increased A levels in AD-H compared to Cont-
H, it was not significant. It is now widely accepted that
A accumulation in the brain does not always corre-
late with neurodegeneration and there are individuals
who have low brain amyloid with neurodegeneration
(A-N+) and ones who have high amyloid without neu-
rodegeneration (A + N-) [13]. We therefore postulate
that this maybe a contributing factor to the low level
of A detected in the hippocampi of AD subjects.
To address this issue in more details, we assessed
A protein levels quantified by western immunoblot-
ting (6E10 antibody) in individual samples of frontal
cortex and hippocampal samples of AD and con-
trol (Supplementary Figure 2). Low A levels (as
compared to Fig. 2) were observed in AD frontal cor-
tex samples 13 and AD hippocampus samples 2, 7,
and 11. High A levels (as compared to Fig. 2) was
observed in control hippocampus sample 3. Overall,
this data supports the growing literature suggesting
that A accumulation does not always correlate with
neurodegeneration.
Next we assessed gene and protein expression of
autophagosome marker LC3B and lysosomal hydro-
lase Cathepsin D in postmortem brain tissues. Fold
change in gene transcription was measured using
comparative Ct method with GAPDH as endogenous
control and Cont-F as the reference biological group.
No significant changes were observed in the expres-
sion of LC3B and Cathepsin D between the different
groups. Also, no significant change in the protein lev-
els of LC3BI (16 kDa) and LC3BII (14 kDa) was
observed between the different groups. However, lev-
els of mature Cathepsin D (30 kDa) was increased
in AD-F and LBD-F regions as compared to Cont-F
(*p < 0.05). We observed increased levels of mature
cathepsin D protein in Cont-H, as compared to Cont-
F; however, this was not significant. Overall, our
findings above were similar to previous studies of
postmortem AD brains [1] showing A accumulation
associated with increased Cathepsin D, indicative of
elevated lysosomal activity in AD, particularly in the
frontal cortex region.
We next assessed gene and protein expression of
autophagy regulators PRKAG2 and TIPRL (Fig. 2).
No significant changes were observed in the gene
or protein expression of TIPRL between different
groups. A small decrease in TIPRL protein was
observed in AD-F and AD-H compared to healthy
control, but was not significant. Notably, a 3-fold
increase in PRKAG2 gene expression was observed
in AD-F as compared to FTD-F, LBD-F, and Cont-
F (*p < 0.05). Despite a marked upregulation of
PRKAG2 gene expression in AD-F, no significant
change in levels of PRKAG2 protein (60 and 75 kDa
isoforms) were observed between different groups.
We observed increased expression of PRKAG2 pro-
tein in frontal cortex compared to hippocampus
in LBD, FTD, and healthy controls; however, this
was not significant. Overall, these findings showing
elevated PRKAG2 gene expression combined with
increased mature Cathepsin D protein is in agreement
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Fig. 1. Gene and protein expression of autophagy markers LC3B and Cathepsin D in AD, FTD, LBD, and control brains. Gene expression
of autophagosome marker LC3B (Hs00797944 s1), lysosomal hydrolase Cathepsin D (CTSD, Hs00157205 m1) and endogenous control
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH, Hs03929097 g1) was conducted on cDNA synthesized from homogenates of frontal
cortex (F) and hippocampus (H) regions of postmortem brain tissues from AD, LBD, FTD, and healthy controls (Cont) using Taqman assays
on the QuantStudio 12K system. Fold change in gene transcripts of LC3B (A) and CTSD (B) was measured using comparative Ct method
with GAPDH as endogenous control and Cont-F as the reference biological group. No significant changes were observed in the expression
of LCB and Cathepsin D between the different groups. Protein levels of LC3B isoforms LC3I (C) and LC3II (D) and mature isoform of
Cathepsin D (E) was also measured using western blotting analysis of the brain homogenates. A representative image of the western blot is
shown here (F). No significant change in levels of LC3I (16 kDa) and LC3II (14 kDa) were observed between the different groups. Levels
of mature Cathepsin D (30 kDa) was increased in AD-F and LBD-F regions as compared to Cont-F (Mean±SD, *p<0.05).
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Fig. 2. Gene and protein expression of autophagy regulators PRKAG2, TIPRL, and A in AD, FTD, LBD, and control brains. Gene expression
of autophagy regulators PRKAG2 (Hs00211903 m1), TIPRL (Hs00295580 m1), and endogenous control GAPDH (Hs03929097 g1) was
conducted on cDNA synthesized from homogenates of frontal cortex (F) and hippocampus (H) regions of postmortem brain tissues from AD,
LBD, FTD, and healthy controls (Cont) using Taqman assays on the QuantStudio 12K system. Fold change in gene transcripts of PRKAG2
(A) and TIPRL (B) was measured using comparative Ct method with GAPDH as endogenous control and Cont-F as the reference biological
group. A 3-fold increase in PRKAG2 transcripts was observed in AD-F as compared to FTD-F, LBD-F and Cont-F (Mean±SD, *p<0.05).
No significant changes were observed in the expression of TIPRL between the different groups. Protein levels of PRKAG2 (C), TIPRL (D),
A (E), and GAPDH (F) was also measured using western blotting analysis of the brain homogenates. A representative image of the western
blot is shown here (G). No significant change in levels of PRKAG2 (60 and 75 kDa isoforms) and TIPRL (32 kDa) were observed between
the different groups. A (4 kDa) was significantly higher in AD-F and LBD-F as compared to Cont-F (Mean±SD, *p < 0.05).
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Fig. 3. Correlation of A and autophagy proteins LC3, Cathepsin D, PRKAG2, and TIPRL mRNA and protein levels. Correlation of A
protein levels (Fig. 2) to protein levels of LC3B isoforms, LC3I (Fig. 2C), LC3II (Fig. 2D), mature Cathepsin D (Fig. 2E), PRKAG2 (Fig.
3C), and TIPRL (Fig. 3D) was done using Pearsons correlation analysis. A levels positively correlated to PRKAG2 levels (r = 0.4809,
p < 0005).
with previous studies showing increased autophagy
induction in AD brain.
PRKAG2 protein levels positively correlate with
increased Aβ accumulation in brain
Our findings above show increased lysosomal
activity and expression of autophagy regulator
PRKAG2 in the AD brain. To determine if A
accumulation is related to changes in PRKAG2 and
autophagy-lysosome pathway in the brain, we per-
formed a Pearson correlation analysis of A levels
to levels of PRKAG2, TIPRL and autophagy mark-
ers LC3B and Cathepsin D. No significant correlation
was observed between A and LC3B, Cathepsin D
or TIPRL. However, a significant positive correlation
was observed between A and PRKAG2 (r = 0.4809,
p = 0.0002). The variability observed in the correla-
tion is possibly due to the significantly higher levels
of A in AD and LBD brains as compared to FTD and
control brains, as shown in Fig. 2. Although PRKAG2
protein was not significantly increased in AD, we
observed that increased A accumulation was asso-
ciated with increased PRKAG2 protein expression.
PRKAG2 is a regulator of stress-induced autophagy
and overall the data suggests that increased PRKAG2
gene expression maybe a response to increased A
accumulation and proteotoxic stress in the brain.
Although there was increased transcript levels of
PRKAG2 in AD, we did not observe its translation
into protein. Growing evidence suggest that the spa-
tial and temporal variations of mRNAs, as well as
the local availability of resources for protein biosyn-
thesis, strongly influence the relationship between
protein levels and their coding transcripts and that
transcript levels are not sufficient to predict protein
levels in many scenarios, especially during cell dys-
function and disease [14]. It is therefore possible that
the lack of translation of increased PRKAG2 gene
expression to protein levels in AD postmortem brains
is possibly due to impaired protein synthesis as a
result of brain atrophy and neurodegeneration.
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DISCUSSION
Autophagy is the primary catabolic pathway acti-
vated by nutrient signaling kinases AMPK and
mTORC1 in response to cellular stressors including
nutrient and energy starvation. Increased induction of
autophagy is relatively frequent in neurodegenerative
diseases, but whether this greater induction rate sig-
nifies disease development is yet to be established.
Our findings showing increased gene expression of
PRKAG2, a positive regulator of autophagy suggest
that it may be a contributing factor to autophagy
induction in AD. The autophagy pathway is impaired
at different steps in neurodegenerative diseases and
mostly associated with increased autophagy initiation
and reduced autophagosome degradation [1, 15]. Our
findings showing increased PRKAG2 gene expres-
sion in AD combined with a positive association
with A levels suggest that PRKAG2 dysfunction
is specific to AD and related to A accumulation, a
pathological hallmark of AD.
Mutations in PRKAG2 are associated with heart
muscle disease [16, 17] and single nucleotide poly-
morphisms (SNPs) in PRKAG2 have shown to been
associated with cognitive impairment and metabolic
dysfunction in old age [18]. Whether these PRKAG2
mutations and SNPs alter PRKAG2 expression in
the brain leading to autophagy dysfunction and accu-
mulation of protein aggregates like A is unknown.
Transcription factor EB (TFEB) is the master regula-
tor of lysosome biogenesis and autophagy, including
PRKAG2 transcription [19]. The role of TFEB in
AD pathogenesis remains contradictory. Increased
TFEB expression and its targets have been observed
in AD patient derived fibroblasts [20] and in the
hippocampus of AD subjects [21]. Similar upregu-
lation of TFEB and its targets have been reported in
transgenic AD mice [22, 23]. These findings strongly
support TFEB gain-of-function in AD may con-
tribute to increased PRKAG2 expression observed
in our findings (Fig. 2). However, in contrast, AD
patient lymphocytes and monocytes has markedly
decreased TFEB expression [24]. In agreement, sub-
cellular fractionation of AD patient brain samples
documented a selective loss of nuclear TFEB [25].
These opposing results demonstrate the need for a
thorough dissection of TFEB dysfunction in AD and
its potential role in regulating PRKAG2 activation in
AD brain.
Our findings suggest that increased PRKAG2 gene
expression could be a response to increased A accu-
mulation and proteotoxic stress in the brain. Increased
autophagy induction has been previously observed in
experimental models in which a disease-related pro-
tein such as -synuclein or SOD1 is overexpressed
[26, 27]. It is possible that autophagy induction in
response to mutant or damaged proteins and aggre-
gates could be compensatory and neuroprotective at
early stages of disease, but may be counterproduc-
tive if lysosomal clearance becomes compromised.
Impaired lysosomal clearance maybe induced by pro-
tein aggregates like A which in turn could also
secondarily elevate autophagy induction, promoting
further damage to the neuronal processes. The molec-
ular mechanisms that link defective autophagy and
A accumulation in AD are unclear and our findings
suggest that the combination of increased autophagy
induction via PRKAG2 and defective clearance of
autophagosomes can create conditions favorable for
A accumulation in AD. Further investigation of
PRKAG2 gene and variants in modulating neuronal
autophagy and A accumulation in disease models
and patients will be critical to establish its pathogenic
role in AD.
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